Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8072880 | 0.87 | USP5 (0.47) | USP5NPC1RAB9AHSD17B3L3MBTL1 | |
| SCHEMBL3682043 | 0.84 | USP5 (0.47) | USP5NPC1RAB9AHSD17B3L3MBTL1 | |
| SCHEMBL2923903 | 0.83 | USP5 (0.64) | USP5NPC1RAB9AHSD17B3L3MBTL1 | |
| SCHEMBL3671743 | 0.79 | USP5 (0.50) | USP5NPC1RAB9AL3MBTL1LMNA | |
| SCHEMBL27724305 | 0.79 | USP5 (0.46) | USP5NPC1RAB9AHSD17B3L3MBTL1 | |
| SCHEMBL3668961 | 0.78 | EPHX1 (0.49) | USP5NPC1RAB9AHSD17B3L3MBTL1 | |
| SCHEMBL3674162 | 0.77 | USP5 (0.44) | USP5NPC1RAB9AHSD17B3L3MBTL1 | |
| SCHEMBL4489859 | 0.75 | HSD17B3 (0.47) | USP5NPC1RAB9AHSD17B3L3MBTL1 | |
| SCHEMBL3676848 | 0.75 | CES2 (0.47) | NPC1RAB9AHSD17B3L3MBTL1HTR7 | |
| SCHEMBL29023173 | 0.75 | NPC1 (0.45) | USP5NPC1RAB9AHSD17B3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010021791-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-09-13 | — | — | US | disclosed |
| US-6147216-A | Intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021791-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | USP5 1362/4885NPC1 1689/4885RAB9A 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.